The Washington Post - The golden ticket for kids 11 and younger is a spot in a covid vaccine trial

EMF does not buy into the fear hysteria of COVID-19,
nor agree with the agenda of mandatory mRNA vaccinations.
User avatar
David McCarthy
Site Admin
Posts: 2892
Joined: Sun Jan 06, 2008 1:09 am
Location: New Zealand
Contact:

The Washington Post - The golden ticket for kids 11 and younger is a spot in a covid vaccine trial

Unread post by David McCarthy »

Just breaks my heart...
The golden ticket for kids 11 and younger is a spot in a covid vaccine trial
The Washington Post - By Tara Bahrampour May 15, 2021

This week, as coronavirus vaccinations for 12- to-15-year-olds began just in time for summer camp, and the Centers for Disease Control and Prevention said vaccinated people could gather indoors without masks, many parents of younger children were left to wonder: When is our turn?
Most will have to wait until at least fall and potentially early 2022 for a coronavirus vaccine to be available to the nation’s approximately 50 million children younger than 12. But for a handful of families, including several in the Washington area, the moment has already arrived.
Pfizer is running a nationwide trial for children 6 months to 11 years old, with one of the sites at the Johns Hopkins Bloomberg School of Public Health in Baltimore. And Moderna is running a trial in the United States and Canada for kids in that age range with a site at the University of Maryland’s School of Medicine that includes locations in Baltimore and Frederick.

As drug companies expand coronavirus vaccine access to children, officials are working to persuade people who are skeptical or unwilling to get vaccinated. (Luis Velarde, Jonathan Baran, Erin Patrick O'Connor/The Washington Post)
Both local trials have enrolled a small number of initial participants to receive lower doses — or in some cases, the same dose as adults — and be monitored for side effects and development of antibodies. The goal is to find the dosage sweet spot by not provoking too strong a reaction while giving children the highest level of protection.
So far, about two dozen area children are in the process of receiving two shots as part of the Pfizer study, which started in late March. In the Moderna study, 10 children received a first dose in late April or May and will get a second after four weeks. More children will be added as the trials progress.
When Carrie Golitko, who has cared for colleagues with covid-19, learned her son and daughter — who are 10 and 8 — had been selected to participate in the Pfizer trial, she could not believe her luck. “I just started crying,” the Takoma Park, Md., pediatrician said. “I was so excited. It was just like a wave of relief washed over me.”
Her children got shots on April 5 and April 26. Her son, Kellan Hayes, 10, said he experienced some temporary chills and a mild fever with brief hallucinations but the payoff was worth it. “I was like the most famous kid in the school,” he said. “Kids came up to me saying, ‘Is it true you got the covid-19 vaccine?’ My mom told us that we’re going to be a part of helping the world and we’re basically making history right now.”
Kellan Hayes, 10, of Takoma Park, Md., after getting his first Pfizer shot in early April. He and his sister are part of the nationwide Pfizer trial for kids younger than 12, the local arm of which is being conducted by doctors at Johns Hopkins University in Baltimore. (Carrie Golitko)
Investigators are scaling the dosing according to age. In the Moderna trial, some children 6 to 11 years old are starting at adult doses or given less; younger children are starting with lower doses. Pfizer is starting children with a third of a dose and scaling up, and then basing younger children’s doses on older children’s responses. The Pfizer vaccine approved last week for 12-to-15-year-olds is the same dose as for adults, but sometimes lower doses are equally effective in children because their immune systems may be more responsive.

Families in the trial monitor their children’s health and side effects, keeping e-diaries and returning to the sites for blood draws to measure antibody response. So far, aside from the expected sore arms and mild temporary symptoms, none of the Moderna participants have reported adverse effects, said James Campbell, principal investigator for the pediatric study for Moderna at the University of Maryland site. The principal investigator for the Pfizer study at the Johns Hopkins site, Kawsar Talaat, said she could not discuss results yet.
The studies are likely to start moving to randomized control trials to measure efficacy by summer, with some children receiving placebos. Pfizer has said it anticipates having results from younger children’s trials as soon as September, but Talaat said the timing “depends on how long it takes to get all the samples and run the assays.” Campbell said randomized trials are projected to start in late summer and continue into winter, with Moderna shots probably becoming available for young children by early 2022.
Vaccines for younger children could fall under the same emergency use authorization as the vaccines for older people, or they could require their own emergency use authorizations or receive full licenses. (Pfizer applied for a full license for its vaccine earlier this month.)
Parents grapple with reality that young children won't be vaccinated soon
After a year of missed school, play dates, sports and visits with grandparents, many families jumped at the chance to get younger children into trials — and back to normal life.

Amanda Debes’s children, who are 6, 4, and 18 months, started asking her about getting vaccinated in January, when their grandparents did. When the coronavirus pandemic hit, she said, “as little as they are, they know their life changed dramatically.”
Debes, a Takoma Park resident, is an assistant scientist at the Johns Hopkins Bloomberg School of Public Health and has studied vaccines, including the mRNA type, which Moderna and Pfizer are. “I had no fears once it became clear it worked,” she said, adding that this type of vaccine is broken down and cleared quickly in the body.

Getting vaccinated will allow the family to get back to cherished activities such as riding the Metro, which her kids love. On Wednesday, as Debes took her youngest child, Lucy, for her second shot of the Pfizer vaccine, her husband took the older boys, who have already had two doses, to the Baltimore aquarium. “That was their incentive the whole time. That’s their favorite thing. The last time we went was March 3rd of 2020,” she said. The family rejoined the aquarium on Wednesday, and on Thursday they went to Target, their first time in a store in a year. “They spent an ungodly amount of time walking every aisle with my niece and they bought some toys,” she said.
Families in the trials represent a tiny fraction of those interested. More than 3,400 have filled out applications for the Moderna trial, but the final number accepted will be between 100 and 200, Campbell said, adding that in all, the trial will involve about 7,300 children. The Pfizer trial will involve about 4,000 children nationwide, Talaat said, adding that it is not yet clear how many will enroll at the Johns Hopkins site. Both studies are still accepting applications.

Rebecca Calloway of Keedysville, Md., and her husband have applied for their 7-year-old daughter and 2-year-old son to participate in the Moderna trial and are waiting to be called. They had already enrolled their son in a meningitis vaccine trial when he was a newborn. But when their 3-year-old daughter, Ailish, died suddenly in December of complications from undiagnosed Type 1 diabetes, their desire to help advances in pediatrics sharpened.
“Our daughter who passed away was an organ donor, and those organ donor recipients are out in the community and they are relying on herd immunity in order to get by,” she said. Her voice broke as she recalled how other family members were unable to visit the hospital because of coronavirus restrictions as their daughter was dying. “It’s our job to be part of helping to protect children,” she added, “and if we can’t put our money where our mouth is, then what are we advocating for?”
Many parents who signed up for the trials are health-care providers. Some inquired with local universities even before they knew trials would be set up there. All said they felt lucky to have gotten spots, given the small number of initial participants.
This is in contrast to a Novavax trial for 12-to-17-year-olds that Campbell is also running, which he said is struggling to find participants for its 40 slots, most likely because children that age can now get vaccinated broadly.
Some have questioned the ethics of vaccinating children, who are less likely than adults to become seriously ill or die of covid-19, while so many countries around the world still lack vaccines for adults. Some parents say they prefer to wait, nervous about injecting their children with a vaccine that is so new.

Of the more than 583,000 coronavirus deaths in the United States, over 300 have been in children younger than 18 — a small percentage but still a higher number than annual pediatric flu deaths, Campbell said. Children have come down with multisystem inflammatory syndrome in children (MIS-C), a condition in which different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes or gastrointestinal organs. Some have experienced long-haul covid-19, in which symptoms persist for months, and it is still unclear what neurological effects the disease will have among survivors.
“We see some really sick children,” Campbell said. “We’ve had multiple children who have been very sick in our intensive care units, on ventilators.”
Parents and children described a combination of selfish and selfless reasons for applying to the trials — and a giddiness at getting in.
“We definitely wanted to be part of the solution and help bring an end to this pandemic,” said Ashley Holmes of Mount Airy, Md., whose son, Cameron, 5, received half the adult dose of the Moderna vaccine. “If kids aren’t getting vaccinated, that’s not going to happen.”
When she picked up Cameron from school to go to the trial site, she said, he ran to the car, yelling, “I’m getting my vaccine today!”
“I was so proud of him, he was so brave,” Holmes said. “There was just kind of excitement in the room. Dr. Campbell came in and gave him a huge high-five and said, ‘You’re the first kids in Frederick to get this vaccine.’ ”

For Holmes, the protection was as important. “Most kids are spared the severe consequences of having covid, but there has been this MIS-C in children, and yes, some have died and been hospitalized, and we still don’t know what the long-term ramifications of having covid are as a child. I don’t want my almost-6-year-old to suffer from some kind of long-term issue because of this.”
Opinion: The CDC shouldn’t have removed restrictions without requiring proof of vaccination
Aside from a sore arm and a little tiredness, Cameron exhibited no ill effects, she said. “He’s been bragging about it, which is cute. I think he feels just proud of himself. … He’s like, ‘Now I don’t have to wear a mask to school,’ and I’m like, ‘You do have to.’ ”
Even for very young children, there is a sense that they are doing something important. Grey Toia, 4, lives in a multigenerational house in Baltimore and saw his grandparents and parents get vaccinated.

“He’s fascinated by the whole process, how his body works, what the vaccine does,” his mother, Justina Wiggins, said, adding that when he got his shot, the clinic staff bucked him up, saying, “You’re a science hero, you’re amazing, thank you for being a scientist with us here today.”
The fact that the vaccine has already been given to millions of adults gave his parents the confidence to enroll him in the Pfizer trial, said his father, David Toia, an educator. “We see this as being good wards of our community and the city where we live,” he added.
The trial administrators allowed ample time for parents and children to ask questions, Wiggins said. (Grey asked whether his dog Beowulf could get covid. Highly unlikely, the doctors told him.) “They were very clear that we could walk away at any time,” she said.
For some participants, daily life won’t alter radically now.

“It doesn’t change our plans because we should all be erring on the safe side of things anyway,” said Shayne James, an operating room nurse from Frederick whose children — Elias, 4; Amelia, 3; and Parker, 3 — got vaccinated through the Moderna trial. “But I think it is sort of a relief to think that they have potential immunity to it.”
Grey Toia received just one-tenth of the adult Pfizer dose, so his parents intend to keep acting as if he is not vaccinated until they learn more about the efficacy of that dose and whether he needs a booster.
Still, they said, it’s a good feeling to have gotten it into his arm. Noting that a year ago, some were predicting that it could be years before a vaccine would become available, David Toia said, “This vaccine has been the moonshot of our time … and to have one small toe in that universe, it’s a story to tell, and beyond being a story to tell, it’s moving one small step away from the fear.”

The golden ticket for kids 11 and younger is a spot in a covid vaccine trial

https://www.washingtonpost.com/dc-md-va ... 12-trials/
But he has nothing on at all, cried at last the whole people....
User avatar
David McCarthy
Site Admin
Posts: 2892
Joined: Sun Jan 06, 2008 1:09 am
Location: New Zealand
Contact:

Dr Ros Jones - COVID-19 child vaccination: safety and ethical concerns

Unread post by David McCarthy »


COVID-19 child vaccination: safety and ethical concerns


May 20, 2021 An open letter from UK doctors to Dr June Raine, Chief Executive, MHRA

--------------------------------------------------------------------------------

Dr Ros Jones
Lead signatory Dr Ros Jones
Retired Consultant Paediatrician

Any medics or scientists who want to sign this open letter should email their name, qualifications and job title to: sign@hartgroup.org
We wish to notify you of our grave concerns regarding all proposals to administer COVID-19 vaccines to children. Recently leaked Government documents suggested that a COVID-19 vaccine rollout in children over 12 years old is already planned for September 2021, and the possibility of children as young as 5 years old being vaccinated in the summer in a worst-case scenario.1

We have been deeply disturbed to hear several Government and SAGE representatives calling in the media for the COVID-19 vaccine rollout to be “turning to children as fast as we can”.2 Teaching materials circulated to London schools contain emotionally loaded questions and inaccuracies3. In addition, there has been disturbing language used by teaching union leaders, implying that coercion of children to accept the COVID-19 vaccines through peer pressure in schools was to be encouraged, despite the fact that coercion to accept a medical treatment is against UK and International Laws and Declarations.4 Rhetoric such as this is irresponsible and unethical, and encourages the public to demand the vaccination of minors with a product still at the research stage and about which no medium- or long-term effects are known, against a disease which presents no material risk to them. A summary of our reasons is given below and a more detailed fully referenced explanation is available.5

Risks and benefits in medical treatments
Vaccines, like any other medical treatment, come with varied risks and benefits. Therefore, we must consider each product, individually, on its merits, and specifically for which patients or sections of the population is the risk/benefit ratio acceptable. For COVID-19 vaccines, the potential benefits are clear for the elderly and vulnerable, however, for children, the balance of benefit and risk would be quite different. We are raising these concerns as part of an informed debate, which is a vital part of the proper, scientific process. We must ensure that there is no repeat of any past tragedies which have occurred especially when vaccines are rushed to market. For example, the swine flu vaccine, Pandemrix, rolled out following the pandemic of 2010, resulted in over one thousand cases of narcolepsy, a devastating brain injury, in children and teenagers, before being withdrawn.6 Dengvaxia, a new vaccine against Dengue, was also rolled out to children ahead of the full trial outcomes, and 19 children died of possible antibody dependent enhancement (ADE) before the vaccine was withdrawn.7 We must not risk a repeat of this with the COVID-19 vaccines, which would not only impact on the children and families affected, but would also have a hugely damaging effect on vaccination uptake in general.

No medical intervention should be introduced on a ‘one size fits all’ basis, but instead should be fully assessed for suitability according to the characteristics of the age cohort and of the individuals concerned, weighing up the risk versus benefit profile for each cohort and the individuals within a group. This approach was outlined last October, by the head of the Government Vaccine Task Force, Kate Bingham, who said “We just need to vaccinate everyone at risk. There’s going to be no vaccination of people under 18. It’s an adult-only vaccine, for people over 50, focusing on health workers and care home workers and the vulnerable.”8

Children do not need vaccination for their own protection
Healthy children are at almost no risk from COVID-19, with risk of death as low as 1 in 2.5 million9. No previously healthy child under the age of 15 died during the pandemic in the UK and admissions to hospital or intensive care are exceedingly rare10 with most children having no or very mild symptoms. Although Long-Covid has been cited as a reason for vaccinating children, there is little hard data. It appears less common and much shorter-lived than in adults and none of the vaccine trials have studied this outcome11 12. The inflammatory condition, PIMS, was listed as a potential adverse effect in the Oxford AstraZeneca children’s trial13. Naturally acquired immunity will give broader and better lasting immunity than vaccination14. Indeed, many children will already be immune15. Individual children at very high risk can already receive vaccination on compassionate grounds16.

Children do not need vaccination to support herd immunity
Already, two thirds of the adult population have received at least one dose of a COVID-19 vaccine17. Models that assume vaccination of children is required to reach herd immunity have failed to account for the proportion who had immunity prior to March 2020 and those who have acquired it naturally18. Recent modelling suggested that the UK had achieved the required herd immunity threshold on 12 April 2021.19

Children do not transmit SARS-CoV-2 as readily as adults, moreover adults living or working with young children are at lower risk of severe COVID-1920. Schools have not been shown to be the focus on spread to the community, teachers have a lower risk of COVID-19 than other working age adults21.

Short-term safety concerns
As of 13th May, the MHRA22 has received a total of 224,544 adverse events, including 1,145 deaths in association with SARS-CoV-2 vaccines. Reports of strokes due to cerebral venous thromboses were initially in low numbers but as awareness increased, many more reports led to the conclusion that AstraZeneca vaccine should not be used for adults under 40 years of age and this unpredicted finding has also led to the suspension of the Oxford AstraZeneca children’s trial.

Similar events have been noted with Pfizer & Moderna vaccines on the US adverse reporting system (VAERS)23 and it is likely that this is a class effect related to production of spike protein. New UK guidelines on managing Vaccine-Induced Thrombotic Thrombocytopenia (VITT)24 include all COVID-19 vaccines in their advice. The possibility of further unexpected safety issues cannot be ruled out. In Israel, where the vaccines have been widely rolled out to young people and teenagers, the Pfizer vaccine has been linked to several cases of myocarditis in young men25 and concerns have been raised about reports of altered menstrual cycles and abnormal bleeding in young women following the vaccine.26

Most concerning with regard to possible vaccination of children, is that there have now been a number of deaths associated with vaccination reported to VAERS in the US, despite the vaccines only being given to children within trials and a very recent rollout to 16-17 year olds27.

Long-term safety concerns
All Phase 3 COVID-19 vaccine trials are ongoing and not due to conclude until late 2022/early 2023. The vaccines are, therefore, currently experimental with only limited short-term and no long-term adult safety data available. In addition, many are using a completely new mRNA vaccine technology, which has never previously been approved for use in humans28. The mRNA is effectively a pro-drug and it is not known how much spike protein any individual will produce. Potential late-onset effects can take months or years to become apparent. The limited children’s trials undertaken to date are totally underpowered to rule out uncommon but severe side effects.

Children have a lifetime ahead of them, and their immunological and neurological systems are still in development, making them potentially more vulnerable to adverse effects than adults. A number of specific concerns have been raised already, including autoimmune disease and possible effects on placentation and fertility.29 A recently published paper raised the possibility that mRNA COVID-19 vaccines could trigger prion-based, neurodegenerative disease30. All potential risks, known and unknown, must be balanced against risks of COVID-19 itself, so a very different benefit/risk balance will apply to children than to adults.

Conclusion
There is important wisdom in the Hippocratic Oath which states, “First do no harm”. All medical interventions carry a risk of harm, so we have a duty to act with caution and proportionality. This is particularly the case when considering mass intervention in a healthy population, in which situation there must be firm evidence of benefits far greater than harms. The current, available evidence clearly shows that the risk versus benefit calculation does NOT support administering rushed and experimental COVID-19 vaccines to children, who have virtually no risk from COVID-19, yet face known and unknown risks from the vaccines. The Declaration of the Rights of the Child states that, “the child, by reason of his physical and mental immaturity, needs special safeguards and care, including appropriate legal protection”.31 As adults we have a duty of care to protect children from unnecessary and foreseeable harm.

We conclude that it is irresponsible, unethical and indeed, unnecessary, to include children under 18 years in the national COVID-19 vaccine rollout. Clinical trials in children also pose huge ethical dilemmas, in light of the lack of potential benefit to trial participants and the unknown risks. The end of the current Phase 3 trials should be awaited as well as several years of safety data in adults, to rule out, or quantify, all potential adverse effects.

We call upon our governments and the regulators not to repeat mistakes from history, and to reject the calls to vaccinate children against COVID-19. Extreme caution has been exercised over many aspects of the pandemic, but surely now is the most important time to exercise true caution – we must not be the generation of adults that, through unnecessary haste and fear, risks the health of children.

Signatories

Dr Rosamond Jones, MD, FRCPCH, retired consultant paediatrician
Lord Moonie, MBChB, MRCPsych, MFCM, MSc, House of Lords, former parliamentary undersecretary of state 2001-2003, former consultant in Public Health Medicine
Prof Anthony Fryer, PhD, FRCPath, Professor of Clinical Biochemistry, Keele University
Professor Karol Sikora, MA, MBBChir, PhD, FRCR, FRCP, FFPM, Dean of Medicine, Buckingham University, Professor of Oncology
Professor Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMed Sci, Professor of Oncology, St Georges Hospital, London
Professor Richard Ennos, MA, PhD. Honorary Professorial Fellow, University of Edinburgh
Professor Anthony J Brookes, Department of Genetics & Genome Biology, University of Leicester
Professor Keith Willison, PhD, Professor of Chemical Biology, Imperial, London
Dr John A Lee, MBBS, PhD, FRCPath, retired Consultant Histopathologist, former Clinical Professor of Pathology at Hull York Medical School
Professor John A Fairclough, BM BS, BMed Sci, FRCS, FFSEM(UK), Professor Emeritus, Honorary Consultant Orthopaedic Surgeon
Dr Alan Mordue, MBChB, FFPH (ret). Retired Consultant in Public Health Medicine & Epidemiology
Dr Elizabeth Evans, MA, MBBS, DRCOG, retired doctor
Mr Malcolm Loudon, MB ChB, MD, FRCSEd, FRCS (Gen Surg). MIHM, VR. Consultant Surgeon
Dr Gerry Quinn, PhD, Microbiologist
Dr C Geoffrey Maidment, MD, FRCP, retired consultant physician
Dr K Singh, MBChB, MRCGP, general practitioner
Dr Pauline Jones MB BS retired general practitioner
Dr Holly Young, BSc, MBChB, MRCP, Consultant physician, Croydon University Hospital
Dr David Critchley, BSc, PhD, 32 years in pharmaceutical R&D as a clinical research scientist.
Dr Padma Kanthan, MBBS, General practitioner
Dr Thomas Carnwath, MBBCh,MA, FRCPsych, FRCGP, consultant psychiatrist
Dr Sam McBride BSc(Hons) Medical Microbiology & Immunobiology, MBBCh BAO, MSc in Clinical Gerontology, MRCP(UK), FRCEM, FRCP(Edinburgh). NHS Emergency Medicine & geriatrics
Dr Helen Westwood MBChB MRCGP DCH DRCOG, general practitioner
Dr M A Bell, MBChB, MRCP(UK), FRCEM, Consultant in Emergency Medicine, UK
Mr Ian F Comaish, MA, BM BCh, FRCOphth, FRANZCO, Consultant ophthalmologist
Dr Jayne LM Donegan MBBS, DRCOG, DCH, DFFP, MRCGP, general practitioner
Dr Dayal Mukherjee, MBBS MSc
Dr Clare Craig, BM,BCh, FRCPath, Pathologist
Mr C P Chilton, MBBS, FRCS, Consultant urologist emeritus
Dr Theresa Lawrie, MBBCh, PhD, Director, Evidence-Based Medicine Consultancy Ltd, Bath
Dr Jason Lester, MRCP, FRCR, Consultant Clinical Oncologist, Rutherford Cancer Centre, Newport
Dr Scott McLachan, FAIDH, MCSE, MCT, DSysEng, LLM, MPhil., Postdoctoral researcher, Risk & Information management Group
Michael Cockayne, MSc, PGDip, SCPHNOH, BA, RN, Occupational health practitioner
Dr John Flack, BPharm, PhD. Retired Director of Safety Evaluation at Beecham Pharmaceuticals 1980-1989 and Senior Vice-president for Drug Discovery 1990-92 SmithKline Beecham
Dr Stephanie Williams, Dermatologist
Dr Greta Mushet, retired Consultant Psychiatrist in Psychotherapy. MBChB, MRCPsych
Dr JE, MBChB, BSc, NHS hospital junior doctor
Mr Anthony Hinton, MBChB, FRCS, Consultant ENT surgeon, London
Dr Elizabeth Corcoran, MBBS,MRCPsych,Psychiatrist,Chair Down’s Syndrome Research Foundation UK
Dr Alan Black, MB BS MSc DipPharmMed, retired pharmaceutical physician
Dr Christina Peers, MBBS,DRCOG,DFSRH,FFSRH, Consultant in Contraception & Reproductive Health
Dr Marco Chiesa, MD, FRCPsych, Consultant Psychiatrist & Visiting Professor, UCL
Elizabeth Burton, MB ChB, retired general practitioner
Noel Thomas, MA, MB ChB, DCH, DObsRCOG, DTM&H, MFHom, retired doctor
Malcolm Sadler, MBBS, FRCGP, retired general practitioner with 37 years in Medical Practice
Dr Ian Bridges, MBBS, Retired general practitioner
Mr T James Royle MBChB, FRCS(Ed), MMedEd, Consultant colorectal surgeon
Dr Fiona Martindale, MbChB, MRCGP, GP in out of hours
Dr Karen Horridge, MB ChB(Hons), MSc, MRCP, FRCPCH, Consultant Paediatrician (Disability)
Mr Christian Duncan, Consultant Plastic Surgeon, MB BCh, BAO, MPhil, FRCSI, FRCS (Plast)
Dr David Bramble, MBChB, MRCPsych, MD. Consultant Psychiatrist
Dr Jessica Robinson, BSc(Hons), MBBS, MRCPsych, MFHom, Psychiatrist & Integrative Medicine Doctor
Katherine MacGilchrist, BSc (Hons) Pharmacology, MSc Epidemiology, CEO, Systematic Review Director, Epidemica Ltd
David Halpin MB BS, FRCS, Orthopaedic and trauma surgeon (retired)
Jemma Dale, BSc (Hons), Biomedical Scientist
Dr Helen Macklin, MBBS, DRCOG, MRCGP, general practitioner
Dr Mark Atkinson, MBBS, BSc (Hons), FRSPH. Retired Medical Doctor
Dr Anne Renfrew, MB ChB, MRCOG, MRCGP, DCH, Retired general practitioner
Dr S Allam, MB ChB, FRCA, Consultant Anaesthetist, UK
Dr David Morris, MBChB, MRCP(UK), General Practitioner
Dr. Peter Chan, BM, MRCS, MRCGP, General Practitioner, Functional medicine practitioner
Dr Sam White, MBChB, MRCGP, General Practitioner, Functional medicine practitioner

Endnotes

1. https://www.dailymail.co.uk/news/articl ... ember.html
2. https://www.dailymail.co.uk/news/articl ... gence.html
3. Critical Thinking Assembly on Vaccines
4. https://www.telegraph.co.uk/news/2021/0 ... s-saypeer/
5. https://www.hartgroup.org/wp-content/up ... cument.pdf
6. https://www.narcolepsy.org.uk/resources ... narcolepsy
7. https://www.sciencemag.org/news/2019/04 ... hilippines
8. https://www.ft.com/content/d2e00128-788 ... e51355a751
9. https://gh.bmj.com/content/bmjgh/5/9/e003094.full.pdf
10. https://doi.org/10.1136/bmj.m3249
11. Illness duration and symptom profile in a large cohort of symptomatic UK school-aged children tested for SARS-CoV-2
12. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease
13. https://www.hartgroup.org/wp-content/up ... eb2021.pdf
14. https://www.nature.com/articles/s41586-021-03207-w
15. https://science.sciencemag.org/content/370/6522/1339
16. https://www.gov.uk/government/publicati ... ember-2020
17. Vaccinations | Coronavirus in the UK (data.gov.uk)
18. https://www.bmj.com/content/370/bmj.m35 ... Do0a6Tsrto
19. Britain will achieve herd immunity by Monday, according to UCL
20. Sharing a household with children and risk of CO VID-19: a study of over 300,000 adults living in healthcare worker households in Scotland
21. https://publichealthscotland.scot/media ... er2020.pdf
22. https://www.gov.uk/government/publicati ... -reactions
23. https://vaers.hhs.gov/data.html
24. Guidance produced from the Expert Haematology Panel (EHP) focussed on Covid-19 Vaccine induced Thrombosis and Thrombocytopenia
25. https://www.timesofisrael.com/israel-sa ... nunder-30/
26. https://www.haaretz.com/israel-news/.pr ... -1.9754865
27. https://vaers.hhs.gov/data.html
28. https://www.immunology.org/coronavirus/ ... r-covid-19
29. https://www.nature.com/articles/s41579-020-00462-y
30. https://scivisionpub.com/pdfs/covid19-r ... e-1503.pdf
31. https://www.ohchr.org/en/professionalin ... s/crc.aspx

COVID-19 child vaccination: safety and ethical concerns – HART
https://www.hartgroup.org/open-letter-c ... ccination/
But he has nothing on at all, cried at last the whole people....
Post Reply

Return to “Covid 19 Pandemic - mRNA Vaccine Safety - Lockdowns”